Öz
Marginal zone lymphomas are the third most common subtype of Non-Hodgkin lymphomas. Nodal marginal zone lymphoma is one of the subtypes of marginal zone lymphoma. It usually occurs after the sixth decade. It is a B-cell lymphoma with an incidence of approximately 1% among all lymphomas. Tumor lysis syndrome (TLS) is rarely seen in the treatment of nodal marginal zone lymphoma. At the same time, TLS is not an expectation in rituximab-bendamustine chemotherapy. Our case presented to our clinic with complaints of nausea and vomiting after rituximab-bendamustine chemotherapy treatment in a patient with a diagnosis of nodal marginal zone lymphoma, and TLS was detected. As a result, the possibility of TLS should be considered when patients present with a giant mass and high LDH level, especially with acute kidney injury, even if they have low-grade lymphoma
Anahtar Kelimeler
Nodal marginal zone lymphoma tumor lysis syndrome low-grade non-Hodgkin lymphoma
Kaynakça
- Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.
- Çetinkaya R., Yılmaz V. T. Tümör Lizis Sendromu. Turkiye Klinikleri J Nephrol-Special Topics. 2014;7(1):74-7.
- Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med 2008;3:161–63.
- Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89 –91.
- Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–50.
- Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946 – 48.
- Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337-41. doi:10.1097/MAJ.0b013e318244db6f
- Naithani R, Bhat A, Bhasin A. Bendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia. Indian J Cancer. 2014;51(3):380-1. doi:10.4103/0019-509X.146740
- Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-66. doi:10.1200/JCO.2010.33.8061
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013 Apr 6;381(9873):1184]. Lancet. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2
Öz
Marjinal zon lenfomalar, Hodgkin dışı lenfomalar arasında en sık görülen üçüncü alt tiptir. Nodal marjinal zon lenfoma, marjinal zon lenfomanın alt tiplerinden biridir. Genellikle altıncı dekattan sonra ortaya çıkar. Tüm lenfomalar içinde yaklaşık %1 görülme oranına sahip, B hücreli bir lenfomadır. Nodal marjinal zon lenfoma tedavisinde, tümör lizis sendromu (TLS) nadir görülmektedir. Aynı zamanda herhangi bir nedenle rituksimab-bendamustin kemoterapisinde de TLS beklenti değildir. Olgumuz, nodal marjinal zon lenfoma tanılı hastada rituximab-bendamustin kemoterapi tedavisi sonrası bulantı ve kusma şikayetleri ile kliniğimize başvurmuş olup TLS saptanmıştır. Sonuç olarak hastalar düşük dereceli lenfoma bile olsa dev kitlesi ve LDH yüksekliğinde özellikle akut böbrek hasarı tablosu ile başvurduğunda TLS olasılığı göz önünde bulundurulmalıdır.
Anahtar Kelimeler
Nodal marjinal zon lenfoma tümör lizis sendromu düşük dereceli non-hodgkin lenfoma
Kaynakça
- Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.
- Çetinkaya R., Yılmaz V. T. Tümör Lizis Sendromu. Turkiye Klinikleri J Nephrol-Special Topics. 2014;7(1):74-7.
- Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med 2008;3:161–63.
- Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89 –91.
- Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–50.
- Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946 – 48.
- Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337-41. doi:10.1097/MAJ.0b013e318244db6f
- Naithani R, Bhat A, Bhasin A. Bendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia. Indian J Cancer. 2014;51(3):380-1. doi:10.4103/0019-509X.146740
- Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-66. doi:10.1200/JCO.2010.33.8061
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013 Apr 6;381(9873):1184]. Lancet. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Yayımlanma Tarihi | 12 Aralık 2022 |
| Gönderilme Tarihi | 5 Şubat 2022 |
| Yayımlandığı Sayı | Yıl 2022Cilt: 61 Sayı: 4 |
